Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$15.19
▲ $0.19 (+1.3%)
Market data updated: 09/19 11:13 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$2.10B
Day Range
$14.76 - $15.43
52-Week Range
$4.82 - $15.87
Beta
—
Next Earnings
02.11.2026
Support
$10.59
Resistance
$15.87
CMPS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+199.0% (1Y)
Strengths: 14/26 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Return on equity (ROE)
Return on equity (ROE): 544.7% — strong
Fundamental
Biggest negative driver
Daily volatility (ATR)
ATR: 5.6% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
60
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $15.19
Evidence: FOMO score jumped from 9 to 50 day-over-day
What happened after
Still awaiting outcome
8d ago · $14.04
Evidence: Euphoria score crossed 55 (now 65)
What happened after
Still awaiting outcome
8d ago · $14.04
Evidence: FOMO score jumped from 21 to 60 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
38
Quality
55
Value
50
Momentum
91
Risk
32
Sentiment
74
Fundamental
48
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Compass Pathways Plc** has focused on its progress toward FDA approval for **COMP360**, a psychedelic treatment for mental health, with a rolling application underway and a potential U.S. launch in **early 2027**. The company is also promoting its **Change the Tune in TRD** educational campaign for healthcare professionals at **Psych Congress 2026**, alongside new data on treatment-resistant depression. Additionally, it received recognition as a **2026 Fierce 50 Breakthrough honoree** and announced employee equity grants to attract talent.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about COMPASS Pathways Plc - American Depository. News trend score: 74. Reason: 6 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
49
🎯 Conviction (vs. Emotion)
52
Psychology
54
Fundamentals
48
Technical
91
Valuation
50
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+21%
Market Narrative
71
Fundamental Reality
52
Narrative Gap
+19
🧠 StockIQ Psychologist
The market behavior for CMPS suggests a **narrative-reality gap** (60 vs. 52) and **euphoric overconfidence** (39/5) as dominant themes. The stock’s 26.1% premium over its 200-day average and positive momentum—despite modest EPS growth—implies investors are prioritizing price appreciation over fundamentals. The lack of panic or herding signals further supports detached optimism. The key question: *Is this momentum self-sustaining, or will fundamentals eventually reassert?*
Updated: 09/09/2026, 04:13 AM
What could change this?
👥 What the crowd believes
"rolling FDA application underway for COMP360, package due in Q4 2026, possible U.S. launch in H1 2027"
"debuting 'Change the Tune in TRD' HCP educational campaign and presenting new HEOR data"
"named a 2026 Fierce 50 Breakthrough honoree"
"participating in Cantor Global Healthcare Conference with psychedelics-focused panel"
🧠 Market Brain events driving this
📈 13D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Jesse Livermore — 72/100
🔴 Weakest match
Samuel Armstrong Nelson — 12/100
🗣️ Why do they disagree?
Based on Thorstein Veblen's documented principles, the model estimates that CMPS’s growth aligns with real value creation, giving it the highest score of 67, while Jesse Livermore’s rule‑based approach finds no clear trend and stays out, reflected in a modest 62. Edgar Lawrence Smith and the efficient‑market view of Malkiel & Bogle assign middle‑range scores (58 and 52) indicating reasonable but not compelling long‑term appeal, whereas Benjamin Graham and Philip Fisher each land at 50, signaling mixed or insufficient fundamentals for a strong buy. The more risk‑averse and cycle‑sensitive investors such as Charles Mackay, Samuel Armstrong Nelson, Gerald Loeb, Walter Bagehot, Peter Lynch, and Howard Marks cluster below 35, flagging crowd delusion, overbought cycles, liquidity and valuation concerns. This spread of scores illustrates how the methodologies diverge—growth‑oriented frameworks view the stock more favorably, while value, risk‑management, and market‑cycle lenses highlight significant cautions.
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 72
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 67
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 58
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 49
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 40
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 34
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 33
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 32
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 30
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 30
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 29
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 12
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 0
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 0 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
544.7%
ROA
-136.8%
ROIC
—
EPS
-$3.08
Cash
$149.61M
Total Debt
$31.63M
Current Ratio
0.77
Debt/Equity
-0.60
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
-$0.57
Tangible Book Value per Share (Tangible NAV)
-$0.57
Sentiment based on basic keywords (not AI) — 6 positive, 12 neutral, 2 negative out of the last 20 articles.
SeekingAlpha · 17.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 15.9.2026
Business Wire · 11.9.2026
Yahoo · 11.9.2026
Yahoo · 10.9.2026
PR Newswire · 10.9.2026
Yahoo · 10.9.2026
Business Wire · 10.9.2026
Yahoo · 10.9.2026
Business Wire · 10.9.2026
Benzinga · 10.9.2026
Yahoo · 9.9.2026
Proactive · 9.9.2026
Yahoo · 9.9.2026
Stocktwits · 9.9.2026
Benzinga · 9.9.2026
Yahoo · 9.9.2026
COMPASS Pathways Plc - American Depository (CMPS) currently has a StockIQ AI score of 60/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
CMPS currently scores 60/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
CMPS's technical score is 91/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Return on equity (ROE): 544.7% — strong; Debt/equity: -0.60; Price is above the 50-day average.
Based on the real signals StockIQ computed: ATR: 5.6% of price; Current ratio: 0.77; Calmar: 0.25 (3y annualized return 20.5% / max drawdown 81.0%).
StockIQ has no recorded dividend payment history for CMPS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Nath Kabir | Tax Withholding in Shares | 3.8.2026 | 5,962 | -5,962 | $11.25 |
| Nath Kabir | Tax Withholding in Shares | 3.8.2026 | 361,028 | -5,962 | $11.25 |
| Tregoning Kathleen | Grant/Award from Employer | 27.5.2026 | 41,119 | +41,119 | — |
| JONAS JEFFREY M | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| Norton David Y | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| McQuade Robert | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| Gover Justin D. | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| Riley Wayne Joseph | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| Karydas Daphne | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| SANTINI GINO | Grant/Award from Employer | 27.5.2026 | 30,158 | +30,158 | — |
| JONAS JEFFREY M | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| SANTINI GINO | Grant/Award from Employer | 27.5.2026 | 30,158 | +30,158 | — |
| Riley Wayne Joseph | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| Norton David Y | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| Gover Justin D. | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| Karydas Daphne | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| Tregoning Kathleen | Grant/Award from Employer | 27.5.2026 | 41,119 | +41,119 | — |
| McQuade Robert | Grant/Award from Employer | 27.5.2026 | 21,110 | +21,110 | — |
| Loxam Teri | Grant/Award from Employer | 26.3.2026 | 157,635 | +157,635 | — |
| Loxam Teri | Grant/Award from Employer | 26.3.2026 | 75,000 | +75,000 | — |
| Goodwin Guy | Grant/Award from Employer | 26.3.2026 | 115,600 | +115,600 | — |
| Nath Kabir | Grant/Award from Employer | 26.3.2026 | 367,815 | +367,815 | — |
| Goodwin Guy | Grant/Award from Employer | 26.3.2026 | 55,000 | +55,000 | — |
| Nath Kabir | Grant/Award from Employer | 26.3.2026 | 175,000 | +175,000 | — |
| Loxam Teri | Grant/Award from Employer | 26.3.2026 | 152,002 | +75,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
14,469,018 shares short as of 2026-08-31 · vs. 13,640,893 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
46.4% of trading volume this week was short selling, vs. 52.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology